{"schema_version":"secwatch.filing_event.v1","accession":"0000875045-26-000073","form_type":"8-K","ticker":"BIIB","cik":"0000875045","company_name":"BIOGEN INC.","filed_at":"2026-07-29T10:10:24+00:00","discovered_at":"2026-07-29T10:15:00.320397+00:00","generated_at":"2026-07-29T10:15:23.669651+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Biogen Q2 revenue $2.7B (+3% YoY); GAAP EPS $0.66, Non-GAAP $3.60; Growth Portfolio up 24% to $1.06B","bullets":["Total revenue $2.7B (+3% YoY); GAAP diluted EPS $0.66 (down 85%), Non-GAAP diluted EPS $3.60 (down 34%).","Growth Portfolio revenue $1.06B (+24% YoY); SPINRAZA $402M (+2%), LEQEMBI in-market $184M (+15%), SKYCLARYS $168M (+29%).","Apellis acquisition closed May 14; SYFOVRE $162M (Biogen $97M), EMPAVELI $46M (Biogen $30M); $0.85 dilution to Non-GAAP EPS in 2026, accretive 2027.","Pipeline: litifilimab SLE data by end-2026; diranersen proof-of-concept in Alzheimer's; pending RayThera acquisition.","Full year 2026 guidance updated reflecting stronger underlying business outlook adjusted for transactions and milestones."],"urls":{"canonical":"https://secwatch.observer/filing/0000875045-26-000073","json":"https://secwatch.observer/filing/0000875045-26-000073.json","markdown":"https://secwatch.observer/filing/0000875045-26-000073.md","text":"https://secwatch.observer/filing/0000875045-26-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/0000875045-26-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875045/000087504526000073/biib-20260729.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-29T10:15:23.669651+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}